Large company small molecule share of Phase I clinical trial starts

STO-REC-STATW560S4T3 Research
61%

Global · 2022

Large company small molecule share of Phase I clinical trial starts worldwide stood at 61% in 2022 (IQVIA).

Original source
Publisher
IQVIA
Authority tier
T3 Research
Locator
Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025
Retrieved
15 Sep 2026
Status
Verified

What the source says

The recent increase in the proportion of small molecule trials in Phase I has been driven by a combination of stabilization of small molecule share among EBPs and an increasing share of small molecule trials among larger companies, where the small molecule share increased from 61% in 2022 to 66% in 2025.

IQVIA Institute, Global R&D Trends 2026 · Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025
Verbatim extraction verified: The figure 61% is directly attested in the quoted passage (Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
IQVIA Institute. (2022). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_W560S45SS5JAN21YBEKN25HTMW
MLA
IQVIA Institute. "Global R&D Trends 2026." 2022, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_W560S45SS5JAN21YBEKN25HTMW.
Chicago
IQVIA Institute. "Global R&D Trends 2026." 2022. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_W560S45SS5JAN21YBEKN25HTMW.
BibTeX
@misc{iqvia2022large25htmw, author = {{IQVIA Institute}}, title = {Global R\&D Trends 2026}, year = {2022}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_W560S45SS5JAN21YBEKN25HTMW}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATW560S4 T3 Research

Primary Source

Publisher
IQVIA Institute · homepage ↗
Authority tier
Tier 3 · Industry & Research
Report
Global R&D Trends 2026
Type
Press release
Published
Locator
Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025
Retrieved
15 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_W560S45SS5JAN21YBEKN25HTMW